BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yanagisawa T, Mori K, Katayama S, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Motlagh RS, Aydh A, König F, Grossmann NC, Pradere B, Miki J, Kimura T, Egawa S, Shariat SF. Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. Int J Clin Oncol 2021. [PMID: 34757531 DOI: 10.1007/s10147-021-02061-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Kageyama S, Yoshida T, Kobayashi K, Wada A, Nagasawa M, Kubota S, Kusaba T, Jo F, Nakagawa S, Johnin K, Narita M, Kawauchi A. Prognostic nutritional index of early post-pembrolizumab therapy predicts long-term survival in patients with advanced urothelial carcinoma. Oncol Lett 2023;25:49. [PMID: 36644144 DOI: 10.3892/ol.2022.13635] [Reference Citation Analysis]
2 Ito K, Kita Y, Kobayashi T. Real‐world outcomes of pembrolizumab for platinum‐refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial‐unfit patients. Int J of Urology 2022. [DOI: 10.1111/iju.15101] [Reference Citation Analysis]
3 Yanagisawa T, Kawada T, Rajwa P, Mostafaei H, Motlagh RS, Quhal F, Laukhtina E, König F, Pallauf M, Pradere B, Karakiewicz PI, Nyirady P, Kimura T, Egawa S, Shariat SF. Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations 2022. [DOI: 10.1016/j.urolonc.2022.06.018] [Reference Citation Analysis]
4 Russell BM, Boussi L, Bellmunt J. Management of Advanced Urothelial Carcinoma in Older and Frail Patients: Have Novel Treatment Approaches Improved Their Care? Drugs Aging 2022;39:271-84. [PMID: 35344197 DOI: 10.1007/s40266-022-00933-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]